BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17237277)

  • 21. Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.
    Kamal A; Suresh P; Ramaiah MJ; Mallareddy A; Imthiajali S; Pushpavalli SN; Lavanya A; Pal-Bhadra M
    Bioorg Med Chem; 2012 Mar; 20(6):2054-66. PubMed ID: 22364746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
    Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation.
    He PX; Zhang J; Che YS; He QJ; Chen Y; Ding J
    Acta Pharmacol Sin; 2014 Dec; 35(12):1546-55. PubMed ID: 25468822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis in cholangiocarcinoma by an andrographolide analogue is mediated through topoisomerase II alpha inhibition.
    Nateewattana J; Dutta S; Reabroi S; Saeeng R; Kasemsook S; Chairoungdua A; Weerachayaphorn J; Wongkham S; Piyachaturawat P
    Eur J Pharmacol; 2014 Jan; 723():148-55. PubMed ID: 24360936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
    Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
    Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
    Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
    Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
    Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
    Fortune JM; Osheroff N
    Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
    Khalil OM; Gedawy EM; El-Malah AA; Adly ME
    Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate.
    Bender RP; Lehmler HJ; Robertson LW; Ludewig G; Osheroff N
    Biochemistry; 2006 Aug; 45(33):10140-52. PubMed ID: 16906772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol oxidation product HU-331 is a potential anticancer cannabinoid-quinone: a narrative review.
    Trac J; Keck JM; Deweese JE
    J Cannabis Res; 2021 Apr; 3(1):11. PubMed ID: 33892826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
    Kizaki H; Onishi Y
    Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines.
    Karki R; Song C; Kadayat TM; Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
    Bioorg Med Chem; 2015 Jul; 23(13):3638-54. PubMed ID: 25936262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
    Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
    Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro.
    Cao B; Chen H; Gao Y; Niu C; Zhang Y; Li L
    Int J Mol Med; 2015 Mar; 35(3):771-6. PubMed ID: 25592869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
    Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
    Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
    Chen W; Shen Y; Li Z; Zhang M; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 86():782-96. PubMed ID: 25240702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
    Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
    Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.